• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Transcriptional Profiling and miRNA-Target Network Analysis Identify Potential Biomarkers for Efficacy Evaluation of Fuzheng-Huayu Formula-Treated Hepatitis B Caused Liver Cirrhosis
【2h】

Transcriptional Profiling and miRNA-Target Network Analysis Identify Potential Biomarkers for Efficacy Evaluation of Fuzheng-Huayu Formula-Treated Hepatitis B Caused Liver Cirrhosis

机译：转录分析和miRNA目标网络分析确定潜在的生物标志物以评估扶正化瘀方治疗乙型肝炎引起的肝硬化的功效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Fuzheng-Huayu (FZHY) formula has been found to have a satisfactory effect on hepatitis B-caused cirrhosis (HBC) treatment. However, the efficacy evaluation of FZHY is often challenging. In this study, a randomized, double-blind and placebo-controlled trial was used to evaluate the therapeutic efficacy of FZHY in HBC treatment. In the trial, 35 medical indexes were detected, and 14 indexes had a statistically-significant difference before compared to after the trial. Importantly, the Child-Pugh score also demonstrated FZHY having therapeutic efficacy. Furthermore, the microRNA (miRNA) profiles of 12 serum samples were detected in FZHY groups, and 112 differential-expressed (DE) miRNAs were determined. Using predicted miRNA targets, 13 kernel miRNAs were identified from the established miRNA-target network. Subsequently, quantitative Real-time Polymerase Chain Reaction (qRT-PCR) was used to validate the expression level of 13 identified miRNAs in the trials. The results showed that nine miRNAs have a statistically-significant difference before compared to after FZHY treatment. By means of a logistic regression model, a miRNA panel with hsa-miR-18a-5p, -326, -1182 and -193b-5p was established, and it can clearly improve the accuracy of the efficacy evaluation of FZHY. This study suggested that the particular miRNAs can act as potential biomarkers and obviously increase the diagnostic accuracy for drug evaluation in HBC treatment progression.
机译：扶正化瘀（FZHY）配方已被发现对乙型肝炎引起的肝硬化（HBC）治疗具有令人满意的效果。但是，FZHY的功效评估通常具有挑战性。在这项研究中，一项随机，双盲和安慰剂对照试验被用来评估FZHY在HBC治疗中的疗效。在该试验中，检测到35种医学指标，其中14项指标在试验前与试验后相比有统计学意义。重要的是，Child-Pugh评分还表明FZHY具有治疗功效。此外，在FZHY组中检测了12个血清样品的microRNA（miRNA）谱，并确定了112个差异表达（DE）miRNA。使用预测的miRNA靶标，从已建立的miRNA靶标网络中鉴定出13种核心miRNA。随后，定量实时聚合酶链反应（qRT-PCR）用于验证试验中13种已鉴定的miRNA的表达水平。结果显示，与FZHY处理后相比，九种miRNA具有统计学上的显着差异。通过逻辑回归模型，建立了具有hsa-miR-18a-5p，-326，-1182和-193b-5p的miRNA面板，可以明显提高FZHY疗效评估的准确性。这项研究表明，特定的miRNA可以充当潜在的生物标志物，并明显提高HBC治疗进展中药物评估的诊断准确性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号